secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rafael Holdings, Inc. (RFL)
CIK:        0001713863
Form:       8-K
Filed at:   2024-03-14T23:59:59+00:00
Accession:  0001213900-24-022271
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rafael Holdings Q2 fiscal 2024 net income $5.9M; Day Three Labs stake raised to 79%
--------------------------------------------------------------------------------

- Net income from continuing ops $5.9M ($0.25 diluted EPS) vs loss of $3.3M (-$0.13) YoY.
- Cash and marketable securities $71.7M at Jan 31, 2024.
- Investment in Cyclo Therapeutics contributed $9.7M unrealized gain; Day Three Labs loss $1.6M.
- Increased ownership in Day Three Labs to 79% majority interest; consolidating results.
- Appointed Dr. John Goldberg as Chief Medical Officer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1713863/000121390024022271/0001213900-24-022271-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1713863/000121390024022271/ea0201707-8k_rafael.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-022271

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer